Reuters logo
BRIEF-Ardelyx says successful trial of hyperphosphatemia treatment
February 15, 2017 / 11:42 AM / 8 months ago

BRIEF-Ardelyx says successful trial of hyperphosphatemia treatment

Feb 15 (Reuters) - Ardelyx Inc

* Ardelyx announces successful phase 3 trial of Tenapanor for hyperphosphatemia in patients with end-stage renal disease

* Tenapanor was well-tolerated in trial

* Ardelyx-Trial results support plans to initiate 2nd phase 3 study of tenapanor for treatment of hyperphosphatemia in esrd patients on dialysis in mid-2017.

* Trial of tenapanor for hyperphosphatemia in patients with end-stage renal disease who are on dialysis met its primary endpoint Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below